Skip to main content

Landry Robert E's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Feb 7, 2023

Accession no.
0001883850-23-000035
Filed
Feb 7, 2023
Trade date
Feb 3-6, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 17 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.16M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Landry Robert ECIK 0001585160Officer (EVP Finance CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 3, 2023Common StockSSaleDisposed−739$764.50−$564,965.532,105Direct
Feb 3, 2023Common StockMOption exerciseAcquired+3,000$381.92+$1,145,76035,105Direct
Feb 3, 2023Common StockFTax withholdingDisposed−2,248$774.29−$1,740,603.9232,857Direct
Feb 6, 2023Common StockSSaleDisposed−51$783.05−$39,935.5532,806Direct
Feb 6, 2023Common StockSSaleDisposed−113$784.27F2−$88,622.5132,693Direct
Feb 6, 2023Common StockSSaleDisposed−78$785.88F3−$61,298.6432,615Direct
Feb 6, 2023Common StockSSaleDisposed−85$786.45F4−$66,848.2532,530Direct
Feb 6, 2023Common StockSSaleDisposed−58$787.47−$45,673.2632,472Direct
Feb 6, 2023Common StockSSaleDisposed−99$788.62F5−$78,073.3832,373Direct
Feb 6, 2023Common StockSSaleDisposed−49$789.05−$38,663.4532,324Direct
Feb 6, 2023Common StockSSaleDisposed−10$790.41−$7,904.132,314Direct
Feb 6, 2023Common StockSSaleDisposed−3$791.00−$2,37332,311Direct
Feb 6, 2023Common StockSSaleDisposed−2$793.33−$1,586.6632,309Direct
Feb 6, 2023Common StockSSaleDisposed−99$794.61F6−$78,666.3932,210Direct
Feb 6, 2023Common StockSSaleDisposed−59$795.41F7−$46,929.1932,151Direct
Feb 6, 2023Common StockSSaleDisposed−18$796.43F8−$14,335.7432,133Direct
Feb 6, 2023Common StockSSaleDisposed−28$797.43−$22,328.0432,105Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 3, 2023Common StockMOption exerciseDisposed−3,000$0.00$0800Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 113 shares of Company stock on February 6, 2023 at prices ranging from $784.02 to $784.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 78 shares of Company stock on February 6, 2023 at prices ranging from $785.85 to $785.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 85 shares of Company stock on February 6, 2023 at prices ranging from $786.03 to $786.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $788.48 to $788.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $794.28 to $794.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

Represents volume-weighted average price of sales of 59 shares of Company stock on February 6, 2023 at prices ranging from $795.26 to $795.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F8

Represents volume-weighted average price of sales of 18 shares of Company stock on February 6, 2023 at prices ranging from $796.35 to $796.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)